Longqi Jiangzhi decoction
Phase 2Small molecule
Longqi Jiangzhi decoction is one of 26 small molecule programs targeting Non-Alcoholic Fatty Liver Disease. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
25
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
31 competitors in Non-Alcoholic Fatty Liver Disease
#DrugCompanyPhaseTrials
1Actos
TakedaApproved
Avandia
Jazz PharmaceuticalsApproved
Bayer Aspirin
BayerApproved
Actigall
AbbVieApproved
Calciferol
Jazz PharmaceuticalsApproved
Uloric
TakedaApproved
Crestor
AstraZenecaApproved
Januvia
ZZydus Therapeutics Inc.
Approved
Jardiance
Boehringer IngelheimApproved
Glucophage
EMD SeronoApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Non-Alcoholic Fatty Liver Disease1 trial
A Clinical Trial of Longqi Jiangzhi Decoction Against Non-alcoholic Fatty Liver Disease
Not yet recruiting·SShanghai Municipal Hospital of Traditional Chinese Medicine·Phase 2·NCT07320456·80 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Longqi Jiangzhi decoction. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details